Table 2 Demographic and clinicopathological characteristics and the associations with H3K9me3 [N (%)]
From: Association of H3K9me3 with breast cancer prognosis by estrogen receptor status
Characteristics | N (%) | H-score ≤ 240 (n = 667) | H-score > 240 (n = 250) | p valuea |
|---|---|---|---|---|
Age (years) | Â | Â | Â | 0.124 |
 < 40 | 181 (19.7) | 135 (20.2) | 46 (18.4) |  |
 40–60 | 606 (66.1) | 447 (67.0) | 159 (63.6) |  |
 ≥ 60 | 130 (14.2) | 85 (12.7) | 45 (18.0) |  |
Menopause | Â | Â | Â | 0.059 |
 Pre- | 506 (57.6) | 380 (59.4) | 126 (52.5) |  |
 Post- | 372 (42.4) | 258 (40.6) | 114 (47.5) |  |
 Missing | 39 | 29 | 10 |  |
Histological grade | Â | Â | Â | 0.020 |
 I/II | 619 (73.3) | 465 (75.5) | 154 (67.5) |  |
 III | 225 (26.7) | 151 (24.5) | 74 (32.5) |  |
 Missing | 73 | 51 | 22 |  |
Tumor size (cm) | Â | Â | Â | 0.605 |
 ≤ 2 | 278 (30.3) | 199 (29.8) | 79 (31.6) |  |
 > 2 | 639 (69.7) | 468 (70.2) | 171 (68.4) |  |
Nodal status | Â | Â | Â | 0.013 |
 Negative | 412 (44.9) | 283 (42.4) | 129 (51.6) |  |
 Positive | 505 (55.1) | 384 (57.6) | 121 (48.4) |  |
Clinical stage | Â | Â | Â | 0.478 |
 I | 165 (18.0) | 114 (17.1) | 51 (20.4) |  |
 II | 491 (53.5) | 359 (53.8) | 132 (52.8) |  |
 III | 261 (28.5) | 194 (29.1) | 67 (26.8) |  |
ER | Â | Â | Â | 0.001 |
 Negative | 247 (26.9) | 159 (23.8) | 88 (35.2) |  |
 Positive | 670 (73.1) | 508 (76.2) | 162 (64.8) |  |
PR |  |  |  |  < 0.001 |
 Negative | 256 (27.9) | 165 (24.8) | 91 (36.4) |  |
 Positive | 660 (72.1) | 501 (75.2) | 159 (63.6) |  |
 Missing | 1 | 1 |  |  |
HER2 | Â | Â | Â | 0.006 |
 Negative | 613 (66.8) | 466 (69.9) | 147 (58.8) |  |
 Equivocal | 76 (8.3) | 52 (7.8) | 24 (9.6) |  |
 Positive | 228 (24.9) | 149 (22.3) | 79 (31.6) |  |